145 related articles for article (PubMed ID: 27118492)
1. Successful treatment of scleromyxedema with melphalan and dexamethasone followed by thalidomide maintenance therapy.
Cao XX; Wang T; Liu YH; Zhou DB; Li J
Leuk Lymphoma; 2016 Dec; 57(12):2934-2936. PubMed ID: 27118492
[No Abstract] [Full Text] [Related]
2. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone.
Yeung CK; Loong F; Kwong YL
Br J Haematol; 2012 May; 157(4):411. PubMed ID: 22429092
[No Abstract] [Full Text] [Related]
3. Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis?
do Prado AD; Schmoeller D; Bisi MC; Piovesan DM; Dias FS; Staub HL
Int J Dermatol; 2012 Aug; 51(8):1013-5. PubMed ID: 21671910
[No Abstract] [Full Text] [Related]
4. [Response to thalidomide in scleromyxedema].
Pascualini MF; Caballero Escuti G; Valente E; Kurpis M; Ruiz Lascano A
Medicina (B Aires); 2013; 73(3):252-4. PubMed ID: 23732202
[TBL] [Abstract][Full Text] [Related]
5. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
Asou N; Izuno Y; Okubo T; Ide K; Ueno H; Kawakita M; Mitsuya H; Hata H
Int J Hematol; 2007 Jul; 86(1):69-71. PubMed ID: 17675270
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma.
Bettolini L; Bighetti S; Maione V; Ghini I; Segala D; Calzavara-Pinton P
Australas J Dermatol; 2024 Jun; 65(4):e104-e107. PubMed ID: 38326991
[No Abstract] [Full Text] [Related]
7. Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone.
Dholaria BR; Cappel M; Roy V
Ann Hematol; 2016 Mar; 95(4):671-2. PubMed ID: 26814914
[No Abstract] [Full Text] [Related]
8. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA
Med Oncol; 2002; 19(4):219-26. PubMed ID: 12512915
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
[TBL] [Abstract][Full Text] [Related]
10. Current treatment for multiple myeloma.
Avigan D; Rosenblatt J
N Engl J Med; 2014 Sep; 371(10):961-2. PubMed ID: 25184869
[No Abstract] [Full Text] [Related]
11. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
12. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of transplant-eligible symptomatic multiple myeloma].
Nakaseko C
Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
[No Abstract] [Full Text] [Related]
15. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights.
Cañueto J; Labrador J; Román C; Santos-Briz A; Contreras T; Gutiérrez NC; García-Sanz R
Eur J Haematol; 2012 May; 88(5):450-4. PubMed ID: 22404151
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of scleromyxedema with oral thalidomide.
Guarenti I; Sebastiani V; Pinto G; de Souza PR; de Almeida H
Int J Dermatol; 2013 May; 52(5):631-2. PubMed ID: 23231733
[No Abstract] [Full Text] [Related]
17. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
[TBL] [Abstract][Full Text] [Related]
18. Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Cheng J; Talamo G; Malysz J; Ochmann M; Lamy T; Loughran TP
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e169-72. PubMed ID: 25037886
[No Abstract] [Full Text] [Related]
19. Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
Hu X; Liu J; Bai C; Wang J; Song X
Eur J Haematol; 2012 Aug; 89(2):183-4. PubMed ID: 22571229
[No Abstract] [Full Text] [Related]
20. Bortezomib plus melphalan and prednisone for multiple myeloma.
Islam A; Ambrus JL
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19073984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
